5.18
16.32 (03.15%)
As of Mar 06, 2024
UNIQURE N.V. [QURE]
As of Feb 28, 2024 | Source: Annual Report to the SEC
Company Overview
Uniqure N.v is a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results.
| Country | United States |
| Phone Number | 1-339-970-7000 |
| Industry | Chemicals And Allied Products |
| Employees | 480 |
| CEO | MATTHEW KAPUSTA |
| Website | www.uniqure.com |
Key fundamental financials loss of $89.57 million Revenue of $1.41 million Current Reporting Revenue Net Income Profit/Loss Sep 2023 $1.41 million $89.57 million loss Jun 2023 $2.42 million $68.47 mil...
uniQure N.V. [QURE] As of Nov 02, 2022| Source: Quarterly Report to the SEC We are a leader in the field of gene therapy, seeking to develop single treatments with potentially curative results for pat...
uniQure N.V. [QURE] As of Aug 08, 2022| Source: Quarterly Report to the SEC We are a leader in the field of gene therapy, seeking to develop single treatments with potentially curative results for pat...
uniQure N.V. [QURE] As of May 09, 2017| Source: Quarterly Report to the SEC We are a leader in the field of gene therapy, seeking to develop single treatments with potentially curative results for pat...
uniQure N.V. [QURE] As of Nov 01, 2017| Source: Quarterly Report to the SEC We are a leader in the field of gene therapy, seeking to develop single treatments with potentially curative results for pat...
Financial Overview
| Revenue | 15,843 K |
| Operating Revenue | -282,871 K |
| Profits | -308,478 K |
| Net Cash | 13,371 K |
Management Effectiveness
| Return on Equity | -148.54% |
| Return on Assets | -37.09% |
| Turnover Ratio | 0.02 K |
| EBIT | -282,871 K |
Profit Ratios
| Gross Margin | 29,471 K |
| Operating Margin | -1785.46% |
| Profit as % of Revenues | -9.55% |
| Profit as % of Assets | -40.15% |
| Profit as % of Stockholder Equity | -148.54% |
Balance Sheet and Cash Flow Measures
| Total Assets | 831,689 K |
| Total Liabilities | 624,019 K |
| Operating Cash Flow | -145,929 K |
| Investing Cash Flow | -205,686 K |
| Financing Cash Flow | 362,721 K |